Next-generation sequencing (NGS) identifies a new breast cancer subtype with HER2 low-amplification status as a candidate for targeted therapy.

Authors

Keywords

Journal

Volume 38, Issue 15_suppl, Pages 553-553

Publisher

American Society of Clinical Oncology (ASCO)

Online

2020-05-25

DOI

10.1200/jco.2020.38.15_suppl.553

Explore over 38,000 international journals covering a vast array of academic fields.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started